全球首款上市的双特异性纳米抗体药物 - 知乎 - 知乎专栏
Ozoralizumab是一款人源化、三价的双特异性纳米抗体，其含有两个靶向TNF-α的VHH和一个靶向人HSA的VHH。 Ozoralizumab采用皮下注射给药，成人剂量为30mg，每4周一次，适用于治疗类风湿性关节炎（RA），尤其适用于对现有治疗反应不充分的RA患者。 Ozoralizumab最初由Ablynx开发，通过将人肿瘤坏血因子 (TNF-α)和人血清白蛋白 (HSA)进行免疫Llama诱导产生抗TNF-α和抗HSA的纳米抗体，并采用噬菌体展示技术进行筛选获得。 2014年9月，Ablynx …
Ozoralizumab(Ozoralizumab) - 药物靶点：TNF-α x albumin_在研 …
两种额外的双特异性抗体（bsAbs）被批准用于非肿瘤适应症，针对VEGF-A/Ang-2的双特异性抗体faricimab（罗氏集团）用于治疗湿性年龄相关性黄斑变性、糖尿病性黄斑水肿和视网膜静脉阻塞后的黄斑水肿，这是首个被批准用于眼科的双特异性抗体，以及针对TNF/人血 ...
Ozoralizumab - Wikipedia
Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases. [1] Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.
Ozoralizumab: First Approval - PubMed
Ozoralizumab (Nanozora ®), a trivalent anti-tumour necrosis factor alpha (TNFα) NANOBODY Ⓡ compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA). In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is ...
Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis
2023年7月11日 · Ozoralizumab (Nanozora), a novel TNF inhibitor, was first approved in Japan in September 2022 as a next-generation antibody for the treatment of rheumatoid arthritis (RA). Ozoralizumab potently inhibits TNF action through two human TNFα-binding domains, and a human serum albumin-binding domain that prolongs its plasma half-life enabling 4-week ...
A novel anti-TNF-α drug ozoralizumab rapidly distributes to …
2022年10月27日 · In clinical studies, the next-generation anti-tumor necrosis factor-alpha (TNF-α) single domain antibody ozoralizumab showed high clinical efficacy shortly after the subcutaneous injection.
Ozoralizumab, a Humanized Anti-TNFα NANOBODY - PubMed
2022年2月22日 · Ozoralizumab is a trivalent, bispecific NANOBODY ® compound that differs structurally from IgGs. In this study we investigated the suppressant effect of ozoralizumab and adalimumab, an anti-TNFα IgG, on arthritis and induction of ADAs in human TNF transgenic mice.
Structural, nonclinical, and clinical features of ozoralizumab: A …
2023年4月1日 · Ozoralizumab (OZR), a novel TNF inhibitor, is an antibody using variable heavy-chain domains of heavy-chain antibody (VHHs) and became the first VHH drug approved for the treatment of rheumatoid arthritis in September 2022. VHHs isolated from camelid heavy-chain antibodies can bind antigens with a single molecule.
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab
Ozoralizumab is a next-generation anti-tumor necrosis factor-α agent that adopts the variable-domain heavy-chain format to enhance the biodistribution to target tissue, prolong the half-life, and reduce unwanted immune responses.
Ozoralizumab: first Nanobody® therapeutic for rheumatoid
Introduction: Ozoralizumab (Nanozora), a novel TNF inhibitor, was first approved in Japan in September 2022 as a next-generation antibody for the treatment of rheumatoid arthritis (RA). Ozoralizumab potently inhibits TNF action through two human TNFα-binding domains, and a human serum albumin-binding domain that prolongs its plasma half-life ...